MacroGenics, Inc. (MGNX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 98 | 76 | 150 | 57 | 148 | 150 | 168 | 110 |
| Operating profit | $m | -73 | -41 | ||||||
| Net profit | $m | -130 | -202 | -120 | -9 | -67 | -75 | - | -116 |
| EPS reported | $ | -1.18 | -0.23 | ||||||
| Operating cashflow per share | $ | -1.28 | -1.00 | ||||||
| Capex per share | $ | 0.03 | 0.03 | ||||||
| FCF per share | $ | -1.31 | -1.03 | ||||||
| Free cash flow | $m | -83 | -66 | ||||||
| Net debt | $m | -115 | -173 | ||||||
| Book value equity | $m | 56 | 43 | ||||||
| Book value per share | $ | 0.88 | 0.67 | ||||||
| Number of shares | m | 63.16 | 63.59 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.83 | 2.37 | ||||||
| P/S LTM | x | 0.68 | 0.61 | ||||||
| P/FCF LTM | x | -1.23 | -1.55 | ||||||
| EV/EBITDA LTM | x | -2.54 | -1.85 | ||||||
| EV/Sales LTM | x | 1.01 | 1.13 | ||||||
| Earnings Yield LTM | % | -73.39% | -5.44% | ||||||
| FCF Yield | % | -81.58% | -64.46% | ||||||
| Quality | |||||||||
| ROE | % | -134.23% | -31.27% | ||||||
| ROIC | % | -32.98% | -2.36% | ||||||
| Operating margin | % | -48.72% | -24.30% | ||||||
| Gross margin | % | +71.12% | +58.70% | ||||||
| FCF/Sales | % | -55.49% | -39.09% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +0.78% | +13.03% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.78 | -1.87 | ||||||
| Net Debt/EBITDA | x | -0.83 | 2.54 | ||||||
| EBIT/Net interest | x | -8.56 | -5.03 | ||||||
| Net debt/market cap | % | +73.94% | +13.08% | ||||||
| Net debt/Equity | x | -2.06 | -4.04 | ||||||
| Gross debt/equity | x | 1.92 | 0.82 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free